Abstract: The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo, into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering, in vivo, into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo, and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo. The SARS-CoV protein is also administered in an immunologically effective amount.